Literature DB >> 10695772

Early occlusion of coronary by-pass associated with the presence of factor V Leiden and the prothrombin 20210A allele: case report.

M L Varela1, Y P Adamczuk, M E Martinuzzo, R R Forastiero, F R Klein, A S Rossi, L O Carreras.   

Abstract

The presence of factor V Leiden mutation and the variation of the prothrombin gene 20210GA have been described as additional risk factors for arterial thrombosis when other acquired or metabolic risk factors are present. We report here a 56-year-old man who developed coronary artery disease since 1980 without any known risk factor and underwent a cardiopulmonary by-pass in 1997. In the first month after surgery, he became symptomatic, and an angiography showed complete occlusion of the grafts and some native coronary arteries. Three months after the second cardiopulmonary by-pass, a thrombophilic state was searched, and plasma levels of lipoprotein (a) (LPa) were measured. The patient is heterozygous for factor V Leiden mutation and has the variation 20210GA of the prothrombin gene and high levels of LPa. These findings induced us to add oral anticoagulation to the aspirin treatment, and the patient is in a good condition 11 months later.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10695772     DOI: 10.1097/00001721-199910000-00008

Source DB:  PubMed          Journal:  Blood Coagul Fibrinolysis        ISSN: 0957-5235            Impact factor:   1.276


  3 in total

Review 1.  The hemostatic defect of cardiopulmonary bypass.

Authors:  Matthew Dean Linden
Journal:  J Thromb Thrombolysis       Date:  2003-12       Impact factor: 2.300

2.  Implantation of left ventricular assist device complicated by undiagnosed thrombophilia.

Authors:  Ondrej Szarszoi; Jiri Maly; Daniel Turek; Marian Urban; Ivo Skalsky; Hynek Riha; Jana Maluskova; Jan Pirk; Ivan Netuka
Journal:  Tex Heart Inst J       Date:  2012

3.  May thrombosis be a cause of congenital extremity absence?

Authors:  Gurkan Genc; Nilgun Erkek Atay; Eda Kepenekli; Nese Yarali
Journal:  Indian J Pediatr       Date:  2007-05       Impact factor: 5.319

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.